The mTOR inhibitor revolution rolls on
Mené sur 111 patients atteints d'un astrocytome sous-épendymaire à cellules géantes associé à une sclérose tubéreuse de Bourneville, cet essai évalue l'efficacité et la toxicité de l'everolimus en traitement de longue durée (durée médiane d'exposition au traitement : 29,3 mois)
In The Lancet Oncology, David Franz and colleagues report findings from the latest in a series of studies of mTOR inhibitors in individuals who have tuberous sclerosis complex (TSC). TSC is genetic, affecting 1 million people worldwide, and characterised by formation of hamartomatous growths throughout the body. Benign tumours in the brain result in seizures, developmental delay, and intellectual disability and a neuropsychiatric phenotype that incudes autism (roughly 50% of affected individuals) ...
The Lancet Oncology , commentaire, 2013